- Home
- ATNM vs MXE Comparison
ATNM vs MXE Comparison
Compare ATNM & MXE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATNM
- MXE
- Stock Information
- Founded
- ATNM 2000
- MXE 1990
- Country
- ATNM United States
- MXE United States
- Employees
- ATNM N/A
- MXE N/A
- Industry
- ATNM Biotechnology: Pharmaceutical Preparations
- MXE Finance Companies
- Sector
- ATNM Health Care
- MXE Finance
- Exchange
- ATNM Nasdaq
- MXE Nasdaq
- Market Cap
- ATNM 50.2M
- MXE 52.2M
- IPO Year
- ATNM N/A
- MXE N/A
- Fundamental
- Price
- ATNM $1.58
- MXE $11.54
- Analyst Decision
- ATNM Strong Buy
- MXE
- Analyst Count
- ATNM 2
- MXE 0
- Target Price
- ATNM $4.50
- MXE N/A
- AVG Volume (30 Days)
- ATNM 116.8K
- MXE 5.8K
- Earning Date
- ATNM 11-13-2025
- MXE 01-01-0001
- Dividend Yield
- ATNM N/A
- MXE 2.66%
- EPS Growth
- ATNM N/A
- MXE N/A
- EPS
- ATNM N/A
- MXE N/A
- Revenue
- ATNM N/A
- MXE N/A
- Revenue This Year
- ATNM N/A
- MXE N/A
- Revenue Next Year
- ATNM N/A
- MXE N/A
- P/E Ratio
- ATNM N/A
- MXE N/A
- Revenue Growth
- ATNM N/A
- MXE N/A
- 52 Week Low
- ATNM $1.03
- MXE $8.40
- 52 Week High
- ATNM $2.41
- MXE $11.51
- Technical
- Relative Strength Index (RSI)
- ATNM 42.17
- MXE 50.45
- Support Level
- ATNM $1.56
- MXE $11.48
- Resistance Level
- ATNM $1.64
- MXE $11.92
- Average True Range (ATR)
- ATNM 0.06
- MXE 0.23
- MACD
- ATNM -0.01
- MXE -0.07
- Stochastic Oscillator
- ATNM 6.67
- MXE 27.27
About ATNM Actinium Pharmaceuticals Inc. (Delaware)
Actinium Pharmaceuticals Inc is a biopharmaceutical company engaged in the development of radiotherapies for patients with cancers lacking effective treatment options. The company's proprietary technology platform utilizes monoclonal antibodies to deliver radioisotopes directly to cells of interest to kill those cells safely and effectively. Its product candidates are Iomab-B, an antibody-drug construct containing iodine 131 (I-131), used for hematopoietic stem cells transplantation in various indications, and Actimab-A, an antibody-drug construct containing actinium 225 (Ac-225), currently in human clinical trials for acute myeloid leukemia.
About MXE Mexico Equity and Income Fund Inc. (The)
Mexico Equity and Income Fund Inc is a closed-end, non-diversified management investment company. It maintains an investment objective of long-term capital appreciation through investments in securities, primarily equity, listed on the Mexican Stock Exchange. The company provides a vehicle to investors who wish to invest in Mexican companies through a managed non-diversified portfolio as part of their overall investment program.